Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy can make you nauseous. Nausea is the most commonly reported side effect of semaglutide, affecting a significant proportion of people starting or increasing their dose. It is usually most noticeable in the first few weeks, tends to settle as your body adjusts, and for most people it does not continue at the same intensity throughout treatment. The key question isn't whether it might happen (it probably will, at least briefly) but how to manage it sensibly and when to take it seriously. As a prescription-only medicine, Wegovy requires clinical assessment before it can be prescribed; a qualified prescriber weighs your full health picture before treatment begins, and they're the right person to talk to if nausea becomes difficult to manage. What follows explains the mechanism behind the nausea, the practical decisions you'll face, and the signs that mean you should seek medical advice promptly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy works by activating GLP-1 receptors, gut-hormone receptors that sit at the centre of how your body regulates appetite and blood sugar. One of the direct effects of that activation is slower gastric emptying: food moves through your stomach more gradually than usual. That slowdown is part of why you feel fuller sooner and eat less. It is also exactly why your stomach can feel unsettled, particularly when it is adjusting to a new dose level.
Semaglutide also acts on receptors in areas of the brain involved in appetite regulation, and these same pathways play a role in nausea signalling. So the nausea isn't a malfunction, it is a direct consequence of the pharmacology. The NHS semaglutide medicines page lists nausea as a very common side effect, meaning it affects more than one in ten people. For context, in the STEP 1 trial (the pivotal clinical study underpinning Wegovy's licence) gastrointestinal side effects were the most frequent reason for discontinuation, though most participants who experienced them continued treatment regardless.
For most people, the nausea peaks in the days immediately after an injection or after stepping up to a higher dose. By the end of the second week at any given dose level, many people report it has softened noticeably. That pattern is worth knowing before your first pen, it sets realistic expectations about timing.
Most of the management here is in your hands day to day, and it starts with a few small adjustments you can trial straight away. Eat smaller amounts at a time, oversized portions make the slow gastric emptying much more uncomfortable. Fatty, fried or very rich foods are the ones most likely to amplify nausea, so it is worth reducing those specifically during dose-adjustment weeks rather than broadly restricting what you eat. Eating slowly matters too; when your stomach empties sluggishly, rushing a meal sends too much at once to a system that isn't moving quickly.
Hydration is underrated here. People who feel nauseated often drink less, which can compound the problem. Small, frequent sips of water throughout the day tend to be easier than large glasses. Cold or carbonated drinks work better for some people; others find plain water at room temperature easier to tolerate.
One quick check worth building into your routine: before each injection, note how you're feeling. If you're already mildly unwell, injecting at that moment can make the nausea feel worse. If you have found that Wegovy is making you nauseous regardless of when you inject, some people find injecting in the evening means any peak nausea happens while they sleep. These are practical adjustments, not clinical instructions, your prescriber can give personalised guidance based on your specific situation, and the Wegovy treatment overview on our site has further background on how treatment is structured.
If you are weighing up the cost side of treatment alongside these practical considerations, our Wegovy price comparison guide sets out what private treatment actually costs in the UK and what a transparent price should include.
Ordinary semaglutide nausea feels like a queasy, unsettled stomach, unpleasant but manageable. There are two scenarios where you should not sit it out and wait.
The first is if nausea is so severe and persistent that you cannot keep fluids down. Prolonged vomiting can cause dehydration, and in people with underlying kidney conditions that can become serious quickly. If you have not been able to keep water down for more than a day, contact your GP or call NHS 111.
The second scenario is more urgent. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known but infrequent side effect of GLP-1 receptor agonist medicines including semaglutide. The warning symptom to know is severe stomach pain, particularly pain that is persistent, that feels different from ordinary nausea, or that spreads to your back, with or without vomiting. That pattern is not typical Wegovy nausea. It warrants same-day emergency assessment; do not delay. You can find the full MHRA Yellow Card reporting service online if you wish to report a suspected side effect.
There are also people for whom the nausea simply does not settle after several weeks at a given dose. If that is your experience, talk to your prescriber about whether remaining at the same dose for longer before any increase might help, that decision is always a clinical one, made with someone who knows your health history. Our clinical team is available seven days a week for patients in our care; get in touch if you have concerns between appointments.
One thing that comes up regularly in practice is people questioning whether the nausea means Wegovy isn't right for them. That conclusion is often premature. The dose-escalation schedule exists precisely because it gives your system time to adjust, 0.25mg is the starting point, and the path to the maintenance dose is deliberately gradual. The nausea profile at 0.25mg looks nothing like the nausea profile at 2.4mg, and for many people the earlier doses are entirely manageable.
The clinical research behind Wegovy consistently shows that gastrointestinal effects, while common, rarely cause people to stop treatment altogether. The evidence from the STEP 1 trial (68 weeks, with semaglutide producing around 15% average weight loss) was gathered in a population that included many participants who experienced exactly this nausea pattern and continued regardless.
It is also worth knowing that nausea is not universal. Some people get through the entire titration with only mild queasiness. Others find it harder. Individual variation is real, and your own experience may be much gentler than you fear. If you have been thinking that Wegovy makes you nauseous in ways that feel hard to manage, reading about other people's experiences on what feeling nauseous on Wegovy actually looks like in practice can be useful context. And for questions about whether you'd be clinically suitable, the most direct next step is to check your eligibility with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.